// App-Quantinova.ai

EP636 : IBRUTINIB TREATMENT IN THE FIRST-LINE SETTING FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: UP TO 7 YEARS OF FOLLOW-UP IN THE RESONATE-2 STUDY

Researchers

Presenter

  • Paolo Ghia

Principal Investigators

  • Tadeusz Robak

  • Alessandra Tedeschi

  • Osnat Bairey

  • Jan Burger

  • Peter Hillmen

  • Steve Coutre

  • Stephen Devereux

  • Sebastian Grosicki

  • Helen McCarthy

  • Jianyong Li

  • David Simpson

  • Fritz Offner

  • Carol Moreno

  • Sandra Dai

  • Anita Szoke

  • James P. Dean

  • Thomas J. Kipps

  • Paul Barr

Medical Centers

  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

  • Wilmot Cancer Institute, University of Rochester Medical Center,Rochester, NY,United States

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • School of Public Health, Silesian Medical University,Katowice,Poland

  • Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland

  • Hospital de la Santa Creu i Sant Pau, Hematology Department, Autonomous University of Barcelona, Barcelona, Spain

  • UCSD Moores Cancer Center,San Diego,United States

  • North Shore Hosp, Auckland, New Zealand

  • Grande Ospedale Metropolitano Niguarda, Milan, Italy

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

  • Rabin Medical Center, Petach Tikvah, Israel

  • The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United Kingdom

  • Royal Bournemouth Hospital, Bournemouth, United Kingdom

  • Stanford Cancer Center, Stanford University School of Medicine,Stanford,United States

  • Jiangsu Cancer Hospital, Nanjing, China

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • Pharmacyclics LLC, an AbbVie Company,Sunnyvale, CA, United States,United States

Locations

  • United States

  • Canada

  • Belgium

  • Poland

  • Spain

  • New Zealand

  • Italy

  • Israel

  • United Kingdom

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • chlorambucil

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved